TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28133919
Drug: Ocriplasmin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocriplasmin (125 μg intravitreal injection)
Study: 28133919
Drug: Placebo (intravitreal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravitreal injection)
Study: 25821725
Drug: 10% KOH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% KOH solution
Study: 22214282
Drug: SAL +
Normalized name: salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAL + LAC combination
Study: 29796866
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg triamcinolone (1 cc)
Study: 29796866
Drug: 10 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 cc (15 μg/ml) oxygen‐ozone (O2‐O3)
Study: 22950711
Drug: Placebo (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (90 mg/d)
Study: 8107615
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg oral oestriol/day for 3 months
Study: 28651442
Drug: BI 695502
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 695502 (1 mg/kg)
Study: 28651442
Drug: US-approved Avastin
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: US-approved Avastin (1 mg/kg)
Study: 28651442
Drug: EU-approved Avastin
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: EU-approved Avastin (1 mg/kg)
Study: 23797426
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of ASA
Study: 23797426
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of clopidogrel
Study: 21102260
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m and carboplatin AUC 6 once every 3 weeks for up to 6 cycles with enzastaurin 1125 or 1200 mg loading dose followed by 500 mg daily until disease progression
Study: 21102260
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m and carboplatin AUC 6 once every 3 weeks for up to 6 cycles without enzastaurin
Study: 21102260
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m and carboplatin AUC 6 once every 3 weeks for up to 6 cycles
Study: 18511306
Drug: Stimulant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant treatment (psychomotor stimulant)
Study: 18511306
Drug: Normal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal treatment (ADHD group assessed once on normal treatment)
Study: 18511306
Drug: Withdrawal from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal from treatment (ADHD group assessed after withdrawing from treatment for at least one week)
Study: 16328487
Drug: Group III
Normalized name: Corticosteroids, potent (group III)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III (moderate/severe nonproliferative DR with laser treatment)
Study: 16328487
Drug: Group IV
Normalized name: Corticosteroids, very potent (group IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group IV (proliferative DR with laser treatment)
Study: 14996265
Drug: Intravenous anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anaesthesia with ketamine and propofol (group P)
Study: 14996265
Drug: Inhalation anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anaesthesia with sevoflurane by LMA (group S)
Study: 10890330
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract EGb 761 (180 mg/d)
Study: 8383769
Drug: Guava fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guava fruit intake (0.5-1.0 kg daily)
Study: 3526853
Drug: 1.55 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.55 mg/kg cibenzoline
Study: 3526853
Drug: 1.80 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.80 mg/kg cibenzoline
Study: 3526853
Drug: 2.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.2 mg/kg cibenzoline
Study: 3526853
Drug: 2.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.6 mg/kg cibenzoline
Study: 21496312
Drug: Observation following
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observation following local treatment of intracranial melanoma metastases with surgery and/or SRS
Study: 15326260
Drug: safinamide (SAF)
DrugBank: Safinamide (DB06654)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: safinamide (SAF) 70 mg/day (range 40 to 90 mg/day)
Study: 11531679
Drug: Metaraminol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaraminol 0.5 mg
Study: 8315260
Drug: Alpha-interferon (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-interferon (10 MU/m2, three times weekly for 4 months)
Study: 26342427
Drug: Ferroquine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferroquine 2 mg/kg plus artesunate
Study: 26342427
Drug: Ferroquine 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferroquine 4 mg/kg plus artesunate
Study: 26342427
Drug: Ferroquine 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferroquine 6 mg/kg plus artesunate
Study: 26342427
Drug: Ferroquine 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferroquine 4 mg/kg monotherapy
Study: 21454017
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive users (third generation)
Study: 21454017
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive users (new generation)
Study: 16414297
Drug: Inhaled glucocorticoid/beta(2)-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocorticoid/beta(2)-adrenergic agonist combination drug
Study: 16414297
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment) for ex-smokers with COPD
Study: 15109558
Drug: Traditional tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional tea preparations of Artemisia annua
Study: 11455223
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg dexamethasone premedication
Study: 11455223
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg dexamethasone premedication
Study: 11455223
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dexamethasone premedication
Study: 9734750
Drug: Omeprazole treatment
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole treatment combined with phylloquinone-restricted diet
Study: 9734750
Drug: Phylloquinone-restricted diet
Normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phylloquinone-restricted diet with omeprazole treatment
Study: 4555981
Drug: 9-tetrahydrocannabinol administered
Normalized name: Δ9-tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9-tetrahydrocannabinol administered by smoking
Study: 22379876
Drug: Standard intensive
Normalized name: MACADAMIA OIL 2 g in 100 g / CERAMIDE NP 0.0006 g in 100 g / PANTHENOL 0.75 g in 100 g / CENTELLA ASIATICA WHOLE 0.003 g in 100 g TOPICAL CREAM [ATO STANDARD INTENSIVECREAM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intensive therapy of diabetic ketoacidosis
Study: 22379876
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy for neuroprotection by actovegin
Study: 22379876
Drug: Reamberin on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reamberin on the background of standard therapy
Study: 22379876
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of actovegin and reamberin
Study: 16814082
Drug: High-dose coenzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose coenzyme Q(10) (10.0 mg/kg/day)
Study: 16814082
Drug: Low-dose coenzyme
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose coenzyme Q(10) (1.0 mg/kg/day)
Study: 12766622
Drug: Mecamylamine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine 7.5 mg
Study: 12766622
Drug: Mecamylamine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine 15 mg
Study: 9327714
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment (HBO) combined with recombinant tissue plasminogen activator (rTPA)
Study: 30940692
Drug: GSK2292767A single
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2292767A single dose (0.05-2 mg)
Study: 30940692
Drug: GSK2292767A repeat
Normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2292767A repeat dose (2 mg for 14 days)
Study: 27074126
Drug: Inositol at
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inositol at 80 mg/kg/d
Study: 27074126
Drug: Inositol at
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inositol at 40 mg/kg/d
Study: 27074126
Drug: Inositol at
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inositol at 10 mg/kg/d
Study: 16896884
Drug: Bicalutamide 150
Normalized name: bicalutamide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 150 mg adjuvant to radiotherapy
Study: 7857734
Drug: Alacepril (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alacepril (37.5 mg)
Study: 25232828
Drug: FOLFOX chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX chemotherapy
Study: 24744152
Drug: Short-interval lower-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-interval lower-dose (SILD) intravenous cyclophosphamide (CYC) - 12 fortnightly pulses at 400 mg followed by 6 monthly pulses
Study: 24744152
Drug: High-dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (HD) intravenous cyclophosphamide (CYC) - 6 monthly pulses followed by two quarterly pulses at 0.5-1.0 g/m(2)
Study: 22113951
Drug: Denosumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (60 mg every 6 months) - long-term group
Study: 22113951
Drug: Denosumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (60 mg every 6 months) - cross-over group
Study: 22113951
Drug: Denosumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (60 mg every 6 months) - both groups
Study: 15941900
Drug: Protein supplement
Normalized name: PROTEIN SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplement (42 g protein, 24 g carbohydrate, 2 g fat)
Study: 15941900
Drug: Carbohydrate supplement
Normalized name: carbohydrate supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate supplement (70 g carbohydrate)
Study: 15941900
Drug: Protein supplement
Normalized name: PROTEIN SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplement
Study: 10739728
Drug: Intense insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense insulin treatment
Study: 10739728
Drug: Standard antidiabetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antidiabetic therapy
Study: 6131148
Drug: Lorazepam (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (4 mg intravenously)
Study: 6131148
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 mg intravenously)
Study: 25224019
Drug: Dehydrated human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dehydrated human amnion/chorion membrane allograft and multilayer compression therapy
Study: 25224019
Drug: Multilayer compression
Normalized name: zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multilayer compression therapy alone
Study: 22763903
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block (20 mL 0.5% ropivacaine)
Study: 17911647
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (AmB) treatment
Study: 17911647
Drug: Sodium antimony
Normalized name: Sodium antimonyl gluconate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium antimony gluconate (SAG) treatment
Study: 12364969
Drug: Anal submucosal
Normalized name: Mephitis mephitis anal gland fluid preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anal submucosal injection (ASI) of amikacin 400 mg daily for ten times
Study: 12364969
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection (IM) of amikacin 400 mg daily for ten times
Study: 7584917
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg isosorbide‐5‐mononitrate
Study: 7584917
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg isosorbide‐5‐mononitrate
Study: 7584917
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg isosorbide‐5‐mononitrate
Study: 498765
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tetraethylthiuramdisulfide (Antabuse) two to four times daily for 4-10 weeks
Study: 25862439
Drug: Treatment discontinuation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment discontinuation
Study: 498765
Drug: Side effects
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Side effects of Antabuse treatment
Study: 498765
Drug: Nickel levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nickel levels during treatment
Study: 30845329
Drug: Vi‐TCV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi‐TCV vaccine
Study: 23460234
Drug: Milk fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk fortified with 600 IU (15 μg) of vitamin D per day for 12 weeks
Study: 23460234
Drug: Milk fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk fortified with 1,000 IU (25 μg) of vitamin D per day for 12 weeks
Study: 23460234
Drug: Unfortified milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfortified milk (control group) 200 ml per day for 12 weeks
Study: 21280197
Drug: MTX 1
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 1 g/m² in 24 hr with intrathecal injection
Study: 21280197
Drug: MTX 3
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 3 g/m² in 3 hr without intrathecal
Study: 7836943
Drug: Heparin‐induced extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin‐induced extracorporeal low‐density lipoprotein/fibrinogen precipitation (HELP)
Study: 31542640
Drug: Chemotherapy regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimens (specific regimens not detailed)
Study: 23185280
Drug: Intravenous amantadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amantadine (400 mg/day)
Study: 23185280
Drug: Amantadine tablet
Normalized name: amantadine Oral Tablet
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine tablet (open-label follow-up)
Study: 21302486
Drug: Fengshikang (FSK)
Normalized name: FSK-5 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fengshikang (FSK) combined with glucocorticoid therapy
Study: 21302486
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) with glucocorticoid therapy
Study: 17351951
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with epirubicin, paclitaxel, and cyclophosphamide plus darbepoetin alpha
Study: 15466946
Drug: Oats (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oats (60 g oatmeal)
Study: 15466946
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 IU) plus Vitamin C (500 mg)
Study: 15466946
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oats and vitamins
Study: 10837840
Drug: Caffeinated beverages
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeinated beverages (tea and coffee with 37.5 mg and 75 mg caffeine in tea, 75 mg and 150 mg caffeine in coffee)
Study: 10837840
Drug: Caffeinated beverages
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeinated beverages (with varying caffeine levels: 0, 25, 50, 100, and 200 mg)
Study: 8403296
Drug: Recombinant tissue
Normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant tissue plasminogen activator (rt-PA) infusion
Study: 8403296
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy with appropriate supplemental measures
Study: 3131404
Drug: gallopamil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: gallopamil (10 mg)
Study: 3131404
Drug: cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cromolyn sodium (20 mg)
Study: 26464454
Drug: THC (Δ9-tetrahydrocannabinol)
Normalized name: Δ9-tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC (Δ9-tetrahydrocannabinol) administered intravenously
Study: 23390362
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (6-month, twice weekly)
Study: 9640082
Drug: NAG urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAG urine activity in patients with massive proteinuria (> 1.5 g/24 h)
Study: 9640082
Drug: NAG values
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAG values above and below 280 nmol/mg of creatinine
Study: 9640082
Drug: NAG values
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAG values higher than 280 nmol/mg of creatinine
Study: 29542334
Drug: Non-biologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-biologic treatment plans (glucocorticoids alone and methotrexate)
Study: 29542334
Drug: Biologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic treatment plans (interleukin-1 blockade and interleukin-6 blockade)
Study: 28599712
Drug: 0.65-g alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.65-g alcohol dose/kg body weight
Study: 26534969
Drug: Modafinil (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (400 mg for 90 days)
Study: 9366542
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol (PEG) preparations
Study: 1583824
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of ST-segment elevation by 50% after 2 hours of treatment
Study: 30570839
Drug: Brigatinib 180
Normalized name: brigatinib 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigatinib 180 mg after a high-fat meal
Study: 30570839
Drug: Brigatinib 180
Normalized name: brigatinib 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigatinib 180 mg after fasting
Study: 30570839
Drug: Treatment-emergent adverse
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-emergent adverse events under fasted conditions
Study: 30570839
Drug: Treatment-emergent adverse
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-emergent adverse events under fed conditions
Study: 30518514
Drug: SlowMo therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SlowMo therapy (new intervention)
Study: 24550332
Drug: Cobicistat (COBI)‐boosted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobicistat (COBI)‐boosted Elvitegravir (EVG/co) (150/150 mg) administered once daily for 10 days
Study: 19953610
Drug: Bilateral superficial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral superficial cervical plexus block (BSCPB) with 20 mL of 0.75% ropivacaine
Study: 17179200
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone therapy (50 microg daily)
Study: 14693980
Drug: SU plus
Normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SU plus metformin
Study: 9678311
Drug: Apolipoprotein E
Normalized name: Apolipoprotein E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apolipoprotein E epsilon4 allele dose
Study: 8036454
Drug: Famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (40 mg at 1830 h)
Study: 22381489
Drug: Low-intensity laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity laser therapy (infrared radiation from a semiconductor diode laser with a wavelength of 810 nm), applied on days 0, 3, 7, and 14 in the first month, and thereafter on every 15th day until complete canine retraction was achieved.
Study: 22381489
Drug: Control side
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control side (no low-intensity laser therapy applied).
Study: 9534293
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg + Hydrochlorothiazide 25 mg (L-HCTZ Group)
Study: 9588918
Drug: High-dose proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose proton and photon irradiation (66.6 or 72 cobalt Gray equivalent, 1.8 CGE/day, 5 fractions/week)
Study: 9588918
Drug: High-dose proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose proton and photon irradiation
Study: 1927914
Drug: Ionic low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ionic low osmolar contrast agent ioxaglate (n = 50)
Study: 30676838
Drug: High-dose investigational
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose investigational Sabin IPV (group A)